
Merck & Co. MRK
Quarterly report 2025-Q3
added 11-05-2025
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NYSESPB |
Shares |
2.53 B |
Market Cap[1] |
$ 253 B |
EBITDA (LTM) |
$ 2.86 B |
P/E (LTM) |
13.46 |
P/S (LTM) |
3.83 |
EPS (LTM) |
7.34 |
Merck & Co., Inc. is a global pharmaceutical company that specializes in the development, manufacturing, and distribution of innovative medicines, vaccines, and animal health products. Founded in 1891, Merck has grown to become one of the largest pharmaceutical companies in the world, with operations in over 140 countries.
The company's mission is to improve the health and well-being of people and animals around the world. Merck is committed to discovering new treatments and cures for some of the most challenging diseases, including cancer, Alzheimer's disease, and HIV/AIDS. The company has a strong pipeline of products in development, with a focus on immunotherapy and oncology.
Merck is also a leader in the development and distribution of vaccines. The company has played a key role in the fight against infectious diseases such as measles, mumps, rubella, and HPV. Merck's vaccines have saved countless lives around the world and continue to be an important tool in preventing disease outbreaks.
In addition to its pharmaceutical and vaccine business, Merck also has a thriving animal health division. The company develops and manufactures products for livestock, pets, and wildlife. Merck's animal health products are used to prevent and treat diseases in animals, improving their health and welfare.
Merck is committed to operating responsibly and sustainably. The company has set ambitious goals to reduce its environmental impact, improve the health and safety of its employees, and support the communities where it operates. Merck has been recognized for its sustainability efforts, including being named to the Dow Jones Sustainability Index for the past 16 years.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | ||
|
Amphastar Pharmaceuticals
AMPH
|
$ 25.27 | -2.43 % | $ 1.22 B | Nasdaq Global Select Market | ||
|
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market | ||
|
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | ||
|
Arbutus Biopharma Corporation
ABUS
|
$ 4.75 | 1.61 % | $ 788 M | Nasdaq Global Select Market | ||
|
Aclaris Therapeutics
ACRS
|
$ 3.26 | -3.12 % | $ 252 M | Nasdaq Global Select Market | ||
|
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | ||
|
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | ||
|
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M | Nasdaq Global Select Market | ||
|
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | ||
|
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | ||
|
Kamada Ltd.
KMDA
|
$ 7.03 | 0.14 % | $ 260 M | Nasdaq Global Select Market | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | ||
|
Ascendis Pharma A/S
ASND
|
$ 220.27 | 4.81 % | $ 5 B | Nasdaq Global Select Market | ||
|
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | ||
|
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
$ 0.91 | -5.01 % | $ 18.7 M | Nasdaq Capital Market | ||
|
Can-Fite BioPharma Ltd.
CANF
|
$ 0.28 | -2.28 % | $ 609 M | NYSE American | ||
|
Alterity Therapeutics Limited
ATHE
|
$ 3.3 | -3.51 % | $ 7.94 B | Nasdaq Capital Market | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | ||
|
AstraZeneca PLC
AZN
|
$ 89.78 | -0.57 % | $ 96.9 B | Nasdaq Global Select Market | ||
|
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | ||
|
Anika Therapeutics
ANIK
|
$ 9.57 | 0.84 % | $ 140 M | Nasdaq Global Select Market,SPB | ||
|
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | ||
|
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market | ||
|
Bellicum Pharmaceuticals
BLCM
|
- | -9.72 % | $ 5.89 M | Nasdaq Capital Market | ||
|
Berkeley Lights
BLI
|
- | -7.31 % | $ 87 M | Nasdaq Global Select Market | ||
|
Benitec Biopharma
BNTC
|
$ 12.05 | -7.06 % | $ 496 M | Nasdaq Capital Market | ||
|
Aytu BioScience
AYTU
|
$ 2.34 | 2.59 % | $ 14.7 M | Nasdaq Capital Market | ||
|
Nymox Pharmaceutical Corporation
NYMX
|
- | -19.68 % | $ 18.4 M | Nasdaq Capital Market | ||
|
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | ||
|
Aptorum Group Limited
APM
|
$ 1.29 | -3.01 % | $ 7.03 M | Nasdaq Global Select Market | ||
|
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | ||
|
Baudax Bio
BXRX
|
- | 0.59 % | $ 63 K | Nasdaq Capital Market | ||
|
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | ||
|
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX | ||
|
Catalyst Biosciences
CBIO
|
$ 14.01 | -8.49 % | $ 922 M | Nasdaq Capital Market | ||
|
ChromaDex Corporation
CDXC
|
- | -0.88 % | $ 598 M | Nasdaq Capital Market | ||
|
Axon Enterprise
AXON
|
$ 566.18 | -2.56 % | $ 42.9 B | Nasdaq Global Select Market,SPB | ||
|
Cerus Corporation
CERS
|
$ 2.16 | 0.47 % | $ 399 M | Nasdaq Global Market | ||
|
Checkpoint Therapeutics
CKPT
|
- | - | $ 169 M | Nasdaq Capital Market | ||
|
Caladrius Biosciences
CLBS
|
- | -16.75 % | $ 25.8 M | Nasdaq Capital Market | ||
|
Clovis Oncology
CLVS
|
- | -7.23 % | $ 13 M | Nasdaq Global Select Market | ||
|
Biogen
BIIB
|
$ 174.42 | 1.11 % | $ 25.4 B | Nasdaq Global Select Market,SPB | ||
|
BioVie
BIVI
|
$ 1.42 | -5.96 % | $ 2.1 M | Nasdaq Capital Market | ||
|
Celldex Therapeutics
CLDX
|
$ 27.36 | -2.09 % | $ 1.76 M | Nasdaq Global Select Market | ||
|
Cortexyme
CRTX
|
- | -1.05 % | $ 67.1 M | Nasdaq Global Select Market,SPB | ||
|
Cellectar Biosciences
CLRB
|
$ 3.63 | -3.97 % | $ 44.4 M | Nasdaq Capital Market | ||
|
Deciphera Pharmaceuticals
DCPH
|
- | - | $ 2.18 B | Nasdaq Global Select Market,SPB | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 11.54 | 0.87 % | $ 746 M | NYSE |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.